<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Regional differences in stage III nonseminoma germ cell tumor patients across seer registries

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,
Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU-Authors

Organization Authors

Co-Authors

Cano Garcia, Cristina

Barletta, Francesco

Tappero, Stefano

Piccinelli, Mattia Luca

Incesu, Reha-Baris

Morra, Simone

Scheipner, Lukas

Tian, Zhe

Saad, Fred

Shariat, Shahrokh F.

Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Purpose: We investigated regional differences in patients with stage III nonseminoma germ cell tumor (NSGCT). Specifically, we investigated differences in baseline patient, tumor characteristics and treatment characteristics, as well as cancer-specific mortality (CSM) across different regions of the United States. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database (2004-2018), patient (age, race/ethnicity), tumor (International Germ Cell Cancer Collaborative Group [IGCCCG] prognostic groups) and treatment (systemic therapy and retroperitoneal lymph dissection [RPLND] status) characteristics were tabulated for stage III NSGCT patients, according to 12 SEER registries representing different geographic regions. Multinomial regression models and multivariable Cox regression models testing for cancer-specific mortality (CSM) were used. Results: In 3,174 stage III NSGCT patients, registry-specific patient counts ranged from 51 (1.5%) to 1630 (51.3%). Differences across registries existed for age (12%-31% for age 40+), race/ethnicity (5%-73% for others than non-Hispanic whites), IGCCCG prognostic groups (24%-43% vs. 14-24% vs. 3%-20%, in respectively poor vs. intermediate vs. good prognosis), systemic therapy (87%-96%) and RPLND status (12%-35%). After adjustment, clinically meaningful inter-registry differences remained for systemic therapy (84%-97%) and RPLND (11%-32%). Unadjusted 5-year CSM rates ranged from 7.1% to 23.3%. Finally in multivariable analyses addressing CSM, 2 registries exhibited more favorable outcomes than SEER registry of reference (SEER Registry 12): SEER Registry 4 (Hazard Ratio (HR): 0.36) and SEER Registry 9 (HR: 0.64;both P = .004). Conclusion: We identified important regional differences in patient, tumor and treatment characteristics, as well as CSM which may be indicative of regional differences in quality of care or expertise in stage III NGSCT management.

Source

Publisher

Elsevier Inc.

Citation

item.page.haspartof

Source

Clinical Genitourinary Cancer

item.page.ispartofseries

item.page.edition

DOI

10.1016/j.clgc.2024.102161

item.page.datauri

item.page.link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators